CardiAction

CardiAction PreScreen: A non-invasive (no blood test required) mass population cardiovascular event risk assessment platform. How identifying the unidentified can reduce the impact of Cardiovascular Disease (CVD) on our populations and the health system. CardiAction ProScreen: An in-person, non-invasive cardiovascular risk assessment performed in pharmacies across Australia and New Zealand. Using advanced biometric telemetry and the CardiAction proprietary dynamic algorithm, ProScreen provides real-time insights into heart and artery health without the need for blood tests or radiation. Cardiovascular disease (CVD) is the #1 cause of death and continues to be responsible for 1/3rd of all deaths worldwide. Responsible for 44,000 deaths annually in Australia and 20 million globally. The Key Advantages of CardiAction The CardiAction Risk Score is a dynamic algorithm that integrates key biomarkers such as age, gender, height, waist circumference, heart rate, and blood pressure data. The model incorporates central systolic blood pressure (cSBP), a recognised predictor of cardiovascular events, such as heart attack and stroke. When using CardiAction PreScreen, cSBP is predicted with approximately ~80% accuracy based on self-reported and estimated biometrics. When using CardiAction ProScreen, cSBP is directly measured with ~99% accuracy in person using Pulse Wave Analysis (PWA). Both methods provide insight into arterial wall stiffness and inflammation. Research has shown that central blood pressure correlates more strongly with vascular disease and clinical outcomes than traditional brachial (arm) blood pressure.